BRPI0516674A - método de análise de mal de alzheimer e reagente de diagnóstico - Google Patents

método de análise de mal de alzheimer e reagente de diagnóstico

Info

Publication number
BRPI0516674A
BRPI0516674A BRPI0516674-8A BRPI0516674A BRPI0516674A BR PI0516674 A BRPI0516674 A BR PI0516674A BR PI0516674 A BRPI0516674 A BR PI0516674A BR PI0516674 A BRPI0516674 A BR PI0516674A
Authority
BR
Brazil
Prior art keywords
alzheimer
amyloid
disease
diagnostic reagent
analysis method
Prior art date
Application number
BRPI0516674-8A
Other languages
English (en)
Inventor
Shigeo Takayama
Yamada Yuji
Original Assignee
Sanko Junyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanko Junyaku Kk filed Critical Sanko Junyaku Kk
Publication of BRPI0516674A publication Critical patent/BRPI0516674A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
    • G01N33/541—Double or second antibody, i.e. precipitating antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MéTODO DE ANáLISE DE MAL DE ALZHEIMER E REAGENTE DE DIAGNóSTICO. A presente invenção objetiva inventar um processo de medição de <225>-amilóide em uma amostra biológica tal como sangue e aplicar o processo para diagnosticar mal de Alzheimer. é possível analisar o mal de Alzheimer através da medição da quantidade total de <225>-amilóide 1-42 e de fragmentos de <225>-amilóide 1-42, cada um dos quais retém o sítio C-terminal do <225>-amilóide 1-42 na amostra biológica através de uma análise imunológica na qual um anticorpo que reconhece o sítio C-terminal do <225>-amilóide 1-42 é usado. é preferível que a análise imunológica seja uma análise imunológica competitiva.
BRPI0516674-8A 2004-10-28 2005-10-27 método de análise de mal de alzheimer e reagente de diagnóstico BRPI0516674A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004314639 2004-10-28
JP2005052003 2005-02-25
PCT/JP2005/019787 WO2006046644A1 (ja) 2004-10-28 2005-10-27 アルツハイマー病の検定方法及び診断試薬

Publications (1)

Publication Number Publication Date
BRPI0516674A true BRPI0516674A (pt) 2008-09-16

Family

ID=36227886

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516674-8A BRPI0516674A (pt) 2004-10-28 2005-10-27 método de análise de mal de alzheimer e reagente de diagnóstico

Country Status (13)

Country Link
US (1) US20080199879A1 (pt)
EP (1) EP1813947A4 (pt)
JP (1) JPWO2006046644A1 (pt)
KR (1) KR20070073778A (pt)
CN (1) CN101048662A (pt)
AU (1) AU2005297854A1 (pt)
BR (1) BRPI0516674A (pt)
CA (1) CA2585148A1 (pt)
IL (1) IL182540A0 (pt)
MX (1) MX2007005053A (pt)
NO (1) NO20072206L (pt)
RU (1) RU2007119535A (pt)
WO (1) WO2006046644A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
KR20150098683A (ko) 2005-12-12 2015-08-28 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
WO2007119685A1 (ja) * 2006-04-13 2007-10-25 Sanko Junyaku Co., Ltd. β－アミロイドの血中分解速度測定によるアルツハイマー病の検定方法及び診断試薬
SG173385A1 (en) 2006-07-14 2011-08-29 Ac Immune S A Ch Humanized antibody against amyloid beta
JP4683298B2 (ja) * 2006-08-21 2011-05-18 アイシン精機株式会社 被検物質の免疫測定方法、及び免疫結合親和性解析の制御方法
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
WO2009016734A1 (ja) * 2007-07-31 2009-02-05 University Of Tsukuba 軽度認知機能障害の検定方法
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
US8445649B2 (en) * 2007-10-29 2013-05-21 Tao Health Life Pharma Co., Ltd. Antibody and use thereof
WO2010034072A1 (en) * 2008-09-26 2010-04-01 The University Of Melbourne Alzheimer's disease biomarkers
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
PT2510359E (pt) 2009-12-11 2015-12-02 Araclón Biotech S L Métodos e reagentes para a deteção melhorada de péptidos beta-amiloides
US20130137120A1 (en) * 2010-01-28 2013-05-30 Panasonic Corporation Amyloid b measurement method
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
US20140094386A1 (en) * 2011-04-12 2014-04-03 David Wilson Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury resulting from a hypoxic event
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
US9541561B2 (en) 2012-06-14 2017-01-10 Electronics And Telecommunications Research Institute Method for diagnosing Alzheimer's disease using biomaterial
JP5991666B2 (ja) * 2012-07-04 2016-09-14 公立大学法人大阪市立大学 アルツハイマー病を検出する方法及びキット
JP2016103980A (ja) * 2013-03-08 2016-06-09 パナソニックヘルスケア株式会社 ハイブリドーマ及びモノクローナル抗体
US11360098B2 (en) * 2015-09-28 2022-06-14 Quest Diagnostics Investments Llc Amyloid beta detection by mass spectrometry
US20200166507A1 (en) * 2016-02-15 2020-05-28 Nobelpharma Co., Ltd. Measurement method and measurement kit for proteins related to genetic diseases
EP3242134A1 (en) * 2016-05-04 2017-11-08 Euroimmun Medizinische Labordiagnostika AG Assay for the diagnosis of a neurological disease
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN113311153B (zh) * 2021-05-12 2023-05-26 华中科技大学 一种用于阿尔茨海默病诊疗一体化的多功能的纳米粒子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411974A1 (en) * 1989-07-05 1991-02-06 N.V. Innogenetics S.A. Monoclonal antibodies to a neurofibrillary tangle antigen
US6610493B1 (en) * 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
DE50103881D1 (de) * 2001-06-12 2004-11-04 Wiltfang Jens Monoklonaler Antikörper, mbAb 1E8, welcher für die zwei ersten N-terminalen Aminosäuren von Amyloid-beta-Peptiden spezifisch ist und dessen Verwendung zum Nachweis von Amyloid-beta Peptiden und/oder sAPPa
WO2003018050A1 (en) * 2001-08-10 2003-03-06 Merck & Co., Inc. Gamma three protease
IL163812A0 (en) * 2002-03-05 2005-12-18 Univ Ramot Immunizing composition and method for inducing an immune response against the -secretase cleavage site of amyloid precursor protein

Also Published As

Publication number Publication date
US20080199879A1 (en) 2008-08-21
MX2007005053A (es) 2007-06-19
WO2006046644A1 (ja) 2006-05-04
KR20070073778A (ko) 2007-07-10
CN101048662A (zh) 2007-10-03
JPWO2006046644A1 (ja) 2008-05-22
IL182540A0 (en) 2007-09-20
NO20072206L (no) 2007-07-30
RU2007119535A (ru) 2008-12-10
CA2585148A1 (en) 2006-05-04
EP1813947A4 (en) 2008-06-11
AU2005297854A1 (en) 2006-05-04
EP1813947A1 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
BRPI0516674A (pt) método de análise de mal de alzheimer e reagente de diagnóstico
DK1889059T3 (da) Fremgangsmåde til forbedret immunoassay
ATE535535T1 (de) Methoden für die diagnose von demenz und anderen neurologischen erkrankungen
BRPI0508515B8 (pt) dispositivo de amostragem de fluido corpóreo
BRPI0112262B8 (pt) processo para detecção e teste para um marcador de uma doença conformacional, kit, processo para identificar um composto, processo para detectar a presença de uma forma patogênica prp sc de proteína de príon, e aparelho
BRPI0923199B8 (pt) método para determinar a presença de anticorpos de fixação de complemento
ES2572372T3 (es) Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1
ATE452343T1 (de) Verbesserte vitamin-d-messung
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
BRPI1015088A2 (pt) peptídeo antigênio ou um fragmento funcional deste, composição farmacêutica, métodos para o tratamento de uma doença ou distúrbio neurodegenerativos tal como tauopatia, para induzir uma resposta imune em um animal, para diagnosticar uma doença, distúrbio ou condição e uma predisposição a doença, distúrbio ou condição, para monitorar a doença residual mínima em um paciente e para prever a receptividade de um paciente, anticorpo, kit de teste, epítopo e linha celular.
ATE461449T1 (de) Verfahren zum nachweis von medizinisch relevanten zuständen in gelösten lbc-proben
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
BR112012009846B8 (pt) método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
ATE474227T1 (de) Bestimmung von felinem und caninem probnp
BR112016004320A2 (pt) biossensor, sistema, kit, métodos de determinação ou de identificação e de quantificação de uma concentração de amônia ou íon amônio, de diagnóstico de uma doença metabólica em um sujeito, de determinação da resposta do paciente a uma terapia, de fabricação de um biossensor, de um sistema ou de qualquer tira de teste e de detecção da presença, ausência, ou quantidade de aminoácidos em uma amostra, e, tira de teste
TW200716981A (en) Method for the quantitative measurement of analytes in a liquid sample by immunochromatography
CY1112423T1 (el) Αναλυτικη συσκευη μικροεπεξεργαστη μιας χρησης
EP1898215A4 (en) METHOD FOR ANALYZING ENDOCRINE SUBSTANCE IN A SPECIMEN
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
BR0012311A (pt) Método para tratamento prévio de amostras para quantificação de colesterol, e método para quantificação de colesterol em lipo-proteìnas especìficas através do uso do método para tratamento prévio
EA201400113A1 (ru) Биологический микрочип для количественного определения иммуноглобулинов классов e и g в биологических жидкостях, способ проведения анализа с его использованием и набор реагентов, его включающий
BR112014012208A2 (pt) ensaio de fibrinogênio
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
WO2009016734A1 (ja) 軽度認知機能障害の検定方法
BRPI0610267B8 (pt) métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: EISAI RANDD MANAGEMENT CO., LTD. (JP)

Free format text: TRANSFERIDO DE: SANKO JUNYAKU CO., LTD.

B10A Cessation: cessation confirmed

Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO, SOLICITADA ATRAVES DA PETICAO NO 018090015157/SP DE 26.03.2009.